SARS-CoV-2 Genomic Surveillance in North Louisiana

摘要 病毒基因组监测对识别SARS-CoV-2变异株具有生物学意义至关重要 关注公共卫生的特征，如逃避体液免疫，增强了 传播性和/或致病潜力增加。这份竞争性修订提案代表了 两个路易斯安那州立大学健康中心(LSUHS)Cobre(氧化还原生物学中心和 心血管疾病[CRBCD]和应用免疫学和病理过程中心 [CAIPP])，并利用现有的机构项目，包括新兴病毒中心 威胁斯(CEVT)CLIA/CAP认证参考实验室，正在进行的新冠肺炎临床研究， 社区大规模疫苗接种和检测服务，以及高效的病毒基因组测序 在整个大流行期间为路易斯安那州北部和中部提供服务的计划。此外，LSUHS 为这些努力与路易斯安那州卫生部(LDH)积极合作，并拥有强大的 将病毒基因组监测数据转化为有利的公共卫生结果的基金会，如 作为对脆弱社区的保护和针对各种令人关切的变种的有针对性的缓解措施。AS 因此，本竞争性修订附录将追求以下两个具体目标：目标1)建立 SARS-CoV-2病毒基因组快速测序和数据共享优先考虑再感染和 以及目标2)进行SARS-CoV-2病毒基因组测序和 具有易感危险因素和/或易感因素的中重度新冠肺炎患者的数据共享 心肺并发症。共同努力，这项工作将极大地加强对 路易斯安那州、德克萨斯州东部和阿肯色州南部出现SARS-CoV-2病毒，造福美国公共卫生和 关于这种毁灭性病毒的进一步研究。

ABSTRACT Viral genomic surveillance is critical for identification of SARS-CoV-2 variants that exhibit biological characteristics of concern for public health, such as escape from humoral immunity, enhanced transmissibility, and/or increased pathogenic potential. This competitive revision proposal represents a collaboration between two LSU Health Shreveport (LSUHS) CoBRE’s (Center for Redox Biology and Cardiovascular Disease [CRBCD] and Center for Applied Immunology and Pathological Processes [CAIPP]) and leverages established institutional programs including the Center for Emerging Viral Threats’ (CEVT) CLIA/CAP certified reference laboratory, ongoing COVID-19 clinical research, community mass vaccination and testing services, and a highly productive viral genome sequencing program that have served North and Central Louisiana throughout the pandemic. Additionally, LSUHS is in active partner with the Louisiana Department of Health (LDH) for these efforts and has a strong foundation for translation of viral genomic surveillance data into favorable public health outcomes, such as protection of vulnerable communities and targeted mitigation steps against variants of concern. As such, this competitive revision supplement will pursue the following two specific aims: Aim 1) Establish rapid SARS-CoV-2 viral genome sequencing and data sharing prioritized by re-infections and infections of vaccine recipients; and Aim 2) Perform SARS-CoV-2 viral genome sequencing and data sharing of moderate to severe COVID-19 patients with predisposing risk factors and/or cardiopulmonary complications. Together, this work will greatly enhance genomic surveillance of SARS-CoV-2 in Louisiana, East Texas, and Southern Arkansas to benefit US public health and advance research regarding this devastating virus.